Cesca Therapeutics Inc. to Exhibit at Several Upcoming Cell Therapy Conferences

Cesca Therapeutics Inc. to Exhibit at Several Upcoming Cell Therapy Conferences

April 25, 2018

RANCHO CORDOVA, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL) today announced that the Company will be exhibiting its full suite of cellular processing solutions, including CAR-TXpress™ for the semi-automated manufacture of CAR-T cell therapies, X-BACS™ for cell isolation and other X-Series™ kits, at the following cell therapy conferences in May:

  • International Society of Cellular Therapy 2018 Annual Meeting

            May 2 – 5, 2018
            Booth: 322
            Palais des congrès de Montréal
            1001, Place Jean-Paul-Riopelle
            Montreal, Canada
            For more information: www.isct2018.com 

  • American Society of Gene and Cell Therapy 2018 Annual Meeting

            May 16 – 19, 2018
            Booth: 417
            Hilton Chicago
            720 South Michigan Avenue
            Chicago, IL 60605
            For more information: www.asgct.org/meetings-workshops/annual-meeting 

  • Phacilitate Automation Special Interest Group 2018

            May 30 – 31, 2018
            The Grove
            Chandler’s Cross,
            Watford WD3 4TG, Hertfordshire
            London, UK
            For more information: www.phacilitateautomation.com 

About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.

Company Contact:
Cesca Therapeutics Inc.
Wendy Samford

Investor Contact:
Rx Communications
Paula Schwartz

Primary Logo

Source: Cesca Therapeutics Inc.